5 May 2025 (32 Days) Date | | - Cons. EPS | - EPS |
10 Mar 2025 Date | | 0.09 Cons. EPS | 0.15 EPS |
5 Nov 2024 Date | | 0.03 Cons. EPS | 0.06 EPS |
6 Aug 2024 Date | | 0.07 Cons. EPS | 0.19 EPS |
7 May 2024 Date | | - Cons. EPS | 0.07 EPS |
5 May 2025 (32 Days) Date | | - Cons. EPS | - EPS |
10 Mar 2025 Date | | 0.09 Cons. EPS | 0.15 EPS |
5 Nov 2024 Date | | 0.03 Cons. EPS | 0.06 EPS |
6 Aug 2024 Date | | 0.07 Cons. EPS | 0.19 EPS |
7 May 2024 Date | | - Cons. EPS | 0.07 EPS |
Medical Devices Industry | Healthcare Sector | Mr. Robert E. Claypoole CEO | NASDAQ (NGS) Exchange | US09075A1088 ISIN |
United States Country | 1,030 Employees | - Last Dividend | - Last Split | - IPO Date |
Bioventus Inc. is a pioneering medical device company that places a strong emphasis on innovating and providing treatments aimed at enhancing the body's intrinsic healing mechanisms. Operating both in the United States and internationally, the company has carved a niche for itself in the medical device industry by offering a wide range of products designed for pain management, surgical solutions, and restorative therapies. With its foundation in 2011 and headquarters in Durham, North Carolina, Bioventus stands as a beacon of advancement in leveraging medical technology to improve patient outcomes.
Pain Treatments: Bioventus' portfolio addresses non-surgical pain through injection therapies and peripheral nerve stimulation products. Key offerings include:
Surgical Solutions: The company provides surgeons with innovative tools and biomaterials for bone and soft tissue procedures, featuring:
Restorative Therapies: Bioventus also addresses neurologic and musculoskeletal recovery, offering devices that aid in rehabilitation from strokes, multiple sclerosis, or central nervous system disorders. Products include:
The company is also developing the Talisman Pulse Generator and Receiver, a potential breakthrough for peripheral nerve stimulation, showcasing Bioventus' commitment to ongoing innovation and improvement in the field of medical devices.